Provider: View Press Release
Type: Link
Title: Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
Description: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab...
Provider: View Press Release
Type: Link
Title: Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
Description: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and...
Provider: View Press Release
Type: Link
Title: Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
Description: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio Paris, October 19, 2023. Sanofi has delivered the first medicines...
Provider: View Press Release
Type: Link
Title: Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
Description: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria Paris and Tarrytown, N.Y. October 20, 2023. The...
Provider: View Press Release
Type: Link
Title: Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Description: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) ...
Provider: View Press Release
Type: Link
Title: Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
Description: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results Paris, October 27, 2023 Q3 2023 sales growth of 3.2%...